Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M412152200 on January 14, 2005

J. Biol. Chem., Vol. 280, Issue 11, 10564-10571, March 18, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/11/10564    most recent
M412152200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, H.
Right arrow Articles by Huang, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, H.
Right arrow Articles by Huang, S.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Signaling Mechanisms Responsible for Lysophosphatidic Acid-induced Urokinase Plasminogen Activator Expression in Ovarian Cancer Cells*

Hongbin Li{ddagger}, Xiaoqin Ye§, Chitladda Mahanivong{ddagger}, Dafang Bian{ddagger}, Jerold Chun§, and Shuang Huang{ddagger}

From the Department of {ddagger}Immunology and §Molecular Biology, The Scripps Research Institute, La Jolla, California 92037

Lysophosphatidic acid (LPA) enhances urokinase plasminogen activator (uPA) expression in ovarian cancer cells; however, the molecular mechanisms responsible for this event have not been investigated. In this study, we used the invasive ovarian cancer SK-OV-3 cell line to explore the signaling molecules and pathways essential for LPA-induced uPA up-regulation. With the aid of specific inhibitors and dominant negative forms of signaling molecules, we determined that the Gi-associated pathway mediates this LPA-induced event. Moreover, constitutively active H-Ras and Raf-1-activating H-Ras mutant enhance uPA expression, whereas dominant negative H-Ras and Raf-1 block LPA-induced uPA up-regulation, suggesting that the Ras-Raf pathway works downstream of Gi to mediate this LPA-induced process. Surprisingly, dominant negative MEK1 or Erk2 displays only marginal inhibitory effect on LPA-induced uPA up-regulation, suggesting that a signaling pathway distinct from Raf-MEK1/2-Erk is the prominent pathway responsible for this process. In this report, we demonstrate that LPA activates NF-{kappa}B in a Ras-Raf-dependent manner and that blocking NF-{kappa}B activation with either non-phosphorylable I{kappa}B or dominant negative I{kappa}B kinase abolished LPA-induced uPA up-regulation and uPA promoter activation. Furthermore, introducing mutations to knock out the NF-{kappa}B binding site of the uPA promoter results in over 80% reduction in LPA-induced uPA promoter activation, whereas this activity is largely intact with the promoter containing mutations in the AP1 binding sites. Thus these results suggest that the Gi-Ras-Raf-NF-{kappa}B signaling cascade is responsible for LPA-induced uPA up-regulation in ovarian cancer cells.


Received for publication, October 27, 2004 , and in revised form, January 12, 2005.

* This work was supported by the National Institute of Health Grant R01 CA93926 and the Department of Army Breast Cancer Research Program Grant DAMD 17-02-0561. This is paper IMM-16982 from The Scripps Research Institute. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Dept of Immunology, IMM-19, The Scripps Research Inst., 10550 N. Torrey Pines Rd., La Jolla, CA 92037. Tel.: 858-784-9211; Fax: 858-784-8472; E-mail: shuang{at}scripps.edu.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Hum Reprod UpdateHome page
X. Ye
Lysophospholipid signaling in the function and pathology of the reproductive system
Hum. Reprod. Update, September 1, 2008; 14(5): 519 - 536.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. Klemm, S. Zimmermann, C. Peschel, T. W. Mak, and J. Ruland
Bcl10 and Malt1 control lysophosphatidic acid-induced NF-{kappa}B activation and cytokine production
PNAS, January 2, 2007; 104(1): 134 - 138.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M.-Z. Cui, E. Laag, L. Sun, M. Tan, G. Zhao, and X. Xu
Lysophosphatidic Acid Induces Early Growth Response Gene 1 Expression in Vascular Smooth Muscle Cells: CRE and SRE Mediate the Transcription
Arterioscler. Thromb. Vasc. Biol., May 1, 2006; 26(5): 1029 - 1035.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Z. Lee, R. F. Swaby, Y. Liang, S. Yu, S. Liu, K. H. Lu, R. C. Bast Jr., G. B. Mills, and X. Fang
Lysophosphatidic Acid Is a Major Regulator of Growth-Regulated Oncogene {alpha} in Ovarian Cancer.
Cancer Res., March 1, 2006; 66(5): 2740 - 2748.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement